Shares of Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) added 17.35% by the end of trading session at $0.76. For the current quarter, the 1 brokerage firms issuing adjusted earnings per share outlook have a consensus forecast of -$0.03/share, which would compare with -$0.08 in the year-ago quarter. The net percentage change is 86.05% over the last 12 months. The trading range in the same period had a highest hit of $0.77 while lowest level was $0.28. At the moment the price is 89.66% above its 50-day moving average and 101.03% above its 200-day moving average.

Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) on March 9, 2017 announced that its Board of Directors has declared a quarterly cash dividend payment on the Company’s 10.50% Series E Convertible Preferred Stock (the “Series E Preferred Stock”).

The quarterly dividend on the Series E Preferred Stock is payable on April 3, 2017 to holders of record at the close of business on March 20, 2017.

The quarterly dividend payment on the Series E Preferred Stock will be $0.65625 per share, which is equivalent to an annualized 10.50% per share, based on the $25.00 per share stated liquidation preference, accruing from January 1, 2017 through March 31, 2017. The Series E Preferred Stock is listed on the NASDAQ Capital Market and trades under the ticker symbol “PPHMP”.

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) last exchanged hands at a price $1.67/share, registering a decline of -18.14%. Among 5 Wall Street analysts tracked by Thomson/First Call, the average PT for CATB is $6.9 but some of them are predicting the price to move at the $14 level. If the most optimistic analysts are correct, the expected total return from the current price would be 738.32. The number of shares traded in most recent trading day was 6.18M shares which averages 1.57M shares a day. Its previous fifty two week high was $7.89 and moved down -73.99% over the same time frame, currently having a market cap around $20.31 million. Shares have risen -52.56% over the trailing six months. At the moment, the stock trades -35.52% below its 50-day moving average and -57.69% below its 200-day moving average.

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) on March 2, 2017 announced that it will report fourth quarter and full year 2016 financial results after the NASDAQ Global Market close on Thursday, March 16, 2017. Jill C. Milne, Ph.D., Chief Executive Officer, will host a conference call and webcast at 4:30pm ET to provide an update on corporate developments and to discuss fourth quarter and last year’s financial results.

At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients and their families. Our SMART (Safely Metabolized And Rationally Targeted) linker drug discovery platform enables us to engineer molecules that simultaneously modulate multiple targets in a disease. We are applying our SMART linker platform to build an internal pipeline of product candidates for rare diseases and plan to pursue partnerships to develop additional product candidates.